サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1379702

リンパ浮腫治療の世界市場 - 産業動向と予測（～2030年）

Global Lymphedema Treatment Market - Industry Trends and Forecast to 2030
出版日: | 発行: Data Bridge Market Research | ページ情報: 英文 341 Pages | 納期: お問合せ

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
リンパ浮腫治療の世界市場 - 産業動向と予測（～2030年）
出版日: 2023年09月01日
発行: Data Bridge Market Research
ページ情報: 英文 341 Pages
納期: お問合せ
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のリンパ浮腫治療の市場規模は、2022年の9億239万2,610米ドルから2030年までに18億6,657万6,800米ドルに達し、2023年～2030年の予測期間にCAGRで9.8%の成長が見込まれています。

当レポートでは、世界のリンパ浮腫治療市場について調査分析し、産業動向と予測、促進要因と抑制要因、企業情勢などの情報を提供しています。

目次

第1章 イントロダクション

第2章 市場セグメンテーション

第3章 エグゼクティブサマリー

第4章 重要考察

  • PESTEL分析
  • ポーターのモデル

第5章 世界のリンパ浮腫治療市場のパイプライン分析

第6章 疫学

第7章 世界のリンパ浮腫治療市場の規制ガイドライン

  • 米国
  • 欧州
  • インド
  • メキシコ
  • カナダ

第8章 市場の概要

  • 促進要因
    • 世界中でのリンパ浮腫患者の増加
    • がんの流行
    • 医療施設の増加
    • リンパ浮腫に対する複数の治療法の利用可能性
  • 抑制要因
    • 高額な治療費
    • 疾患についての認識の欠如
  • 機会
    • 医薬品の承認の増加
    • 主要企業によるパートナーシップと合意の増加
  • 課題
    • リンパ浮腫の永久的な治療法がないこと
    • 限定的な償還シナリオ

第9章 世界のリンパ浮腫治療市場：治療タイプ別

  • 概要
  • 圧迫療法
    • 圧迫ポンプ
    • 弾性着衣
    • 弾性包帯
    • その他
  • 手術
    • リンパ静脈移植
    • リンパ管細静脈吻合術
    • 脂肪吸引
    • その他
  • 薬物療法
    • 非ステロイド性抗炎症薬（NSAIDs）
    • レチノイド
    • 抗生物質
    • その他
  • レーザー治療
  • その他

第10章 世界のリンパ浮腫治療市場：タイプ別

  • 概要
  • 続発性リンパ浮腫
  • 原発性リンパ浮腫
    • 前立腺リンパ浮腫（メージュ病）
    • 先天性リンパ浮腫
    • 遅発性リンパ浮腫

第11章 世界のリンパ浮腫治療市場：患部別

  • 概要
  • 下肢
  • 上肢
  • 生殖器

第12章 世界のリンパ浮腫治療市場：年齢層別

  • 概要
  • 成人
  • 高齢者
  • 小児

第13章 世界のリンパ浮腫治療市場：投与経路別

  • 概要
  • 経口
  • 注射可能
  • 局所

第14章 世界のリンパ浮腫治療市場：エンドユーザー別

  • 概要
  • 病院
  • 専門クリニック
  • 外来手術センター
  • その他

第15章 世界のリンパ浮腫治療市場：流通チャネル別

  • 概要
  • 薬局
  • 直接提供
  • その他

第16章 世界のリンパ浮腫治療市場：地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • ロシア
    • スペイン
    • トルコ
    • オランダ
    • スイス
    • ベルギー
    • ポーランド
    • オーストリア
    • ハンガリー
    • ノルウェー
    • アイルランド
    • リトアニア
    • その他の欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • シンガポール
    • フィリピン
    • タイ
    • マレーシア
    • ベトナム
    • その他のアジア太平洋
  • 南米
    • ブラジル
    • アルゼンチン
    • ペルー
    • その他の南米
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • エジプト
    • アラブ首長国連邦
    • イスラエル
    • クウェート
    • その他の中東・アフリカ

第17章 世界のリンパ浮腫治療市場、企業情勢

  • 企業シェア分析：世界
  • 企業シェア分析：北米
  • 企業シェア分析：欧州
  • 企業シェア分析：アジア太平洋

第18章 企業プロファイル

  • TACTILE MEDICAL
  • ESSITY (BSN MEDICAL GMBH)
  • 3M
図表
  • 18.4 CARDINAL HEALTH 313
    • 18.4.1 COMPANY SNAPSHOT 313
    • 18.4.2 REVENUE ANALYSIS 313
    • 18.4.3 COMPANY SHARE ANALYSIS 314
    • 18.4.4 PRODUCT PORTFOLIO 314
    • 18.4.5 RECENT DEVELOPMENT 314
  • 18.5 LOHMANN & RAUSCHER GMBH & CO. KG 315
    • 18.5.1 COMPANY SNAPSHOT 315
    • 18.5.2 COMPANY SHARE ANALYSIS 315
    • 18.5.3 PRODUCT PORTFOLIO 316
    • 18.5.4 RECENT DEVELOPMENT 316
  • 18.6 AIROS MEDICAL, INC. 317
    • 18.6.1 COMPANY SNAPSHOT 317
    • 18.6.2 PRODUCT PORTFOLIO 317
    • 18.6.3 RECENT DEVELOPMENT 317
  • 18.7 AVET PHARMACEUTICALS INC. 318
    • 18.7.1 COMPANY SNAPSHOT 318
    • 18.7.2 PRODUCT PORTFOLIO 318
    • 18.7.3 RECENT DEVELOPMENT 318
  • 18.8 BIOCOMPRESSION SYSTEMS 319
    • 18.8.1 COMPANY SNAPSHOT 319
    • 18.8.2 PRODUCT PORTFOLIO 319
    • 18.8.3 RECENT DEVELOPMENT 319
  • 18.9 CONVATEC INC. 321
    • 18.9.1 COMPANY SNAPSHOT 321
    • 18.9.2 PRODUCT PORTFOLIO 321
    • 18.9.3 RECENT DEVELOPMENT 321
  • 18.10 HERANTIS PHARMA PLC 322
    • 18.10.1 COMPANY SNAPSHOT 322
    • 18.10.2 RECENT DEVELOPMENT 322
  • 18.11 HUNTLEIGH HEALTHCARE LIMITED 323
    • 18.11.1 COMPANY SNAPSHOT 323
    • 18.11.2 PRODUCT PORTFOLIO 323
    • 18.11.3 RECENT DEVELOPMENT 323
  • 18.12 JUZO 324
    • 18.12.1 COMPANY SNAPSHOT 324
    • 18.12.2 PRODUCT PORTFOLIO 324
    • 18.12.3 RECENT DEVELOPMENT 324 
  • 18.13 KOYA MEDICAL 325
    • 18.13.1 COMPANY SNAPSHOT 325
    • 18.13.2 PRODUCT PORTFOLIO 325
    • 18.13.3 RECENT DEVELOPMENT 325
  • 18.14 MEDI GMBH & CO. KG 326
    • 18.14.1 COMPANY SNAPSHOT 326
    • 18.14.2 PRODUCT PORTFOLIO 326
    • 18.14.3 RECENT DEVELOPMENT 326
  • 18.15 MEGO AFEK LTD 327
    • 18.15.1 COMPANY SNAPSHOT 327
    • 18.15.2 PRODUCT PORTFOLIO 327
    • 18.15.3 RECENT DEVELOPMENT 327
  • 18.16 PAUL HARTMANN AG 329
    • 18.16.1 COMPANY SNAPSHOT 329
    • 18.16.2 REVENUE ANALYSIS 329
    • 18.16.3 PRODUCT PORTFOLIO 330
    • 18.16.4 RECENT DEVELOPMENTS 330
  • 18.17 SANYLEG SRL A SOCIO UNICO 331
    • 18.17.1 COMPANY SNAPSHOT 331
    • 18.17.2 PRODUCT PORTFOLIO 331
    • 18.17.3 RECENT DEVELOPMENT 331
  • 18.18 SIGVARIS GROUP 332
    • 18.18.1 COMPANY SNAPSHOT 332
    • 18.18.2 PRODUCT PORTFOLIO 332
    • 18.18.3 RECENT DEVELOPMENTS 333
  • 18.19 SMITH +NEPHEW 334
    • 18.19.1 COMPANY SNAPSHOT 334
    • 18.19.2 REVENUE ANALYSIS 334
    • 18.19.3 PRODUCT PORTFOLIO 335
    • 18.19.4 RECENT DEVELOPMENT 335
  • 18.20 THERMOTEK 336
    • 18.20.1 COMPANY SNAPSHOT 336
    • 18.20.2 PRODUCT PORTFOLIO 336
    • 18.20.3 RECENT DEVELOPMENT 336

19 QUESTIONNAIRE 337

20 RELATED REPORTS 341

LIST OF TABLES

  • TABLE 1 PIPELINE ANALYSIS FOR LYMPHEDEMA TREATMENT: 65
  • TABLE 2 AN ANNUAL SURVEY OF HOSPITALS IN THE U.S., PUBLISHED IN 2021 74
  • TABLE 3 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 81
  • TABLE 4 GLOBAL COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION 2021-2030 (USD THOUSAND) 81
  • TABLE 5 GLOBAL COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 82
  • TABLE 6 GLOBAL COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 82
  • TABLE 7 GLOBAL COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 83
  • TABLE 8 GLOBAL SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 84
  • TABLE 9 GLOBAL SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 84
  • TABLE 10 GLOBAL DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 86
  • TABLE 11 GLOBAL DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 86
  • TABLE 12 GLOBAL LASER THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 87
  • TABLE 13 GLOBAL OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 88
  • TABLE 14 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 91
  • TABLE 15 GLOBAL SECONDARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 91
  • TABLE 16 GLOBAL PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 92
  • TABLE 17 GLOBAL PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 92
  • TABLE 18 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 96
  • TABLE 19 GLOBAL LOWER EXTREMITY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 96
  • TABLE 20 GLOBAL UPPER EXTREMITY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 97
  • TABLE 21 GLOBAL GENITALIA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 98
  • TABLE 22 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 101
  • TABLE 23 GLOBAL ADULT IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 101
  • TABLE 24 GLOBAL GERIATRIC IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 102
  • TABLE 25 GLOBAL PEDIATRIC IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 102
  • TABLE 26 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 105
  • TABLE 27 GLOBAL ORAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 105
  • TABLE 28 GLOBAL INJECTABLE IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 106
  • TABLE 29 GLOBAL TOPICAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 107
  • TABLE 30 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 110
  • TABLE 31 GLOBAL HOSPITAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 110
  • TABLE 32 GLOBAL SPECIALITY CLINICS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 111
  • TABLE 33 GLOBAL AMBULATORY SURGICAL CENTERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 112
  • TABLE 34 GLOBAL OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 113
  • TABLE 35 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 116
  • TABLE 36 GLOBAL PHARMACY STORES IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 116
  • TABLE 37 GLOBAL DIRECT TENDER IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 117
  • TABLE 38 GLOBAL OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 118
  • TABLE 39 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 123
  • TABLE 40 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 124
  • TABLE 41 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 124
  • TABLE 42 NORTH AMERICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 124
  • TABLE 43 NORTH AMERICA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 125
  • TABLE 44 NORTH AMERICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 125
  • TABLE 45 NORTH AMERICA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 125
  • TABLE 46 NORTH AMERICA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 125
  • TABLE 47 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 126
  • TABLE 48 NORTH AMERICA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 126
  • TABLE 49 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 126
  • TABLE 50 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 126
  • TABLE 51 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 127
  • TABLE 52 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 127
  • TABLE 53 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 127
  • TABLE 54 U.S. LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 128
  • TABLE 55 U.S. COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 128
  • TABLE 56 U.S. COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 128
  • TABLE 57 U.S. COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 128
  • TABLE 58 U.S. SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 129
  • TABLE 59 U.S. DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 129
  • TABLE 60 U.S. LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 129
  • TABLE 61 U.S. PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 129
  • TABLE 62 U.S. LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 130
  • TABLE 63 U.S. LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 130
  • TABLE 64 U.S. LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 130
  • TABLE 65 U.S. LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 130
  • TABLE 66 U.S. LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 131
  • TABLE 67 CANADA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 131
  • TABLE 68 CANADA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 131
  • TABLE 69 CANADA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 131
  • TABLE 70 CANADA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 132
  • TABLE 71 CANADA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 132
  • TABLE 72 CANADA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 132
  • TABLE 73 CANADA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 132
  • TABLE 74 CANADA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 133
  • TABLE 75 CANADA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 133
  • TABLE 76 CANADA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 133
  • TABLE 77 CANADA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 133
  • TABLE 78 CANADA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 133
  • TABLE 79 CANADA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 134
  • TABLE 80 MEXICO LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 135
  • TABLE 81 MEXICO COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 135
  • TABLE 82 MEXICO COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 135
  • TABLE 83 MEXICO COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 135
  • TABLE 84 MEXICO SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 136
  • TABLE 85 MEXICO DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 136
  • TABLE 86 MEXICO LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 136
  • TABLE 87 MEXICO PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 136
  • TABLE 88 MEXICO LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 137
  • TABLE 89 MEXICO LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 137
  • TABLE 90 MEXICO LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 137
  • TABLE 91 MEXICO LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 137
  • TABLE 92 MEXICO LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 137
  • TABLE 93 EUROPE LYMPHEDEMA TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 138
  • TABLE 94 EUROPE LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 138
  • TABLE 95 EUROPE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 139
  • TABLE 96 EUROPE COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 139
  • TABLE 97 EUROPE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 139
  • TABLE 98 EUROPE SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 139
  • TABLE 99 EUROPE DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 140
  • TABLE 100 EUROPE LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 140
  • TABLE 101 EUROPE PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 140
  • TABLE 102 EUROPE LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 140
  • TABLE 103 EUROPE LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 141
  • TABLE 104 EUROPE LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 141
  • TABLE 105 EUROPE LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 141
  • TABLE 106 EUROPE LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 141
  • TABLE 107 GERMANY LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 142
  • TABLE 108 GERMANY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 142
  • TABLE 109 GERMANY COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 142
  • TABLE 110 GERMANY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 142
  • TABLE 111 GERMANY SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 143
  • TABLE 112 GERMANY DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 143
  • TABLE 113 GERMANY LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 143
  • TABLE 114 GERMANY PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 143
  • TABLE 115 GERMANY LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 144
  • TABLE 116 GERMANY LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 144
  • TABLE 117 GERMANY LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 144
  • TABLE 118 GERMANY LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 144
  • TABLE 119 GERMANY LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 145
  • TABLE 120 FRANCE LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 146
  • TABLE 121 FRANCE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 146
  • TABLE 122 FRANCE COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 146
  • TABLE 123 FRANCE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 146
  • TABLE 124 FRANCE SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 147
  • TABLE 125 FRANCE DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 147
  • TABLE 126 FRANCE LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 147
  • TABLE 127 FRANCE PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 147
  • TABLE 128 FRANCE LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 148
  • TABLE 129 FRANCE LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 148
  • TABLE 130 FRANCE LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 148
  • TABLE 131 FRANCE LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 148
  • TABLE 132 FRANCE LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 149
  • TABLE 133 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 150
  • TABLE 134 UNITED KINGDOM COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 150
  • TABLE 135 UNITED KINGDOM COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 150
  • TABLE 136 UNITED KINGDOM COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 150
  • TABLE 137 UNITED KINGDOM SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 151
  • TABLE 138 UNITED KINGDOM DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 151
  • TABLE 139 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 151
  • TABLE 140 UNITED KINGDOM PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 151
  • TABLE 141 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 152
  • TABLE 142 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 152
  • TABLE 143 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 152
  • TABLE 144 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 152
  • TABLE 145 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 153
  • TABLE 146 ITALY LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 154
  • TABLE 147 ITALY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 154
  • TABLE 148 ITALY COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 154
  • TABLE 149 ITALY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 154
  • TABLE 150 ITALY SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 155
  • TABLE 151 ITALY DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 155
  • TABLE 152 ITALY LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 155
  • TABLE 153 ITALY PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 155
  • TABLE 154 ITALY LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 156
  • TABLE 155 ITALY LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 156
  • TABLE 156 ITALY LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 156
  • TABLE 157 ITALY LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 156
  • TABLE 158 ITALY LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 156
  • TABLE 159 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 157
  • TABLE 160 RUSSIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 157
  • TABLE 161 RUSSIA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 157
  • TABLE 162 RUSSIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 157
  • TABLE 163 RUSSIA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 158
  • TABLE 164 RUSSIA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 158
  • TABLE 165 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 158
  • TABLE 166 RUSSIA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 158
  • TABLE 167 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 159
  • TABLE 168 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 159
  • TABLE 169 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 159
  • TABLE 170 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 159
  • TABLE 171 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 160
  • TABLE 172 SPAIN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 161
  • TABLE 173 SPAIN COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 161
  • TABLE 174 SPAIN COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 161
  • TABLE 175 SPAIN COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 161
  • TABLE 176 SPAIN SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 162
  • TABLE 177 SPAIN DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 162
  • TABLE 178 SPAIN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 162
  • TABLE 179 SPAIN PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 162
  • TABLE 180 SPAIN LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 163
  • TABLE 181 SPAIN LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 163
  • TABLE 182 SPAIN LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 163
  • TABLE 183 SPAIN LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 163
  • TABLE 184 SPAIN LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 164
  • TABLE 185 TURKEY LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 165
  • TABLE 186 TURKEY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 165
  • TABLE 187 TURKEY COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 165
  • TABLE 188 TURKEY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 165

LIST OF FIGURES

  • FIGURE 1 GLOBAL LYMPHEDEMA TREATMENT MARKET: SEGMENTATION 46
  • FIGURE 2 GLOBAL LYMPHEDEMA TREATMENT MARKET: DATA TRIANGULATION 49
  • FIGURE 3 GLOBAL LYMPHEDEMA TREATMENT MARKET: DROC ANALYSIS 50
  • FIGURE 4 GLOBAL LYMPHEDEMA TREATMENT MARKET: GLOBAL VS REGIONAL ANALYSIS 51
  • FIGURE 5 GLOBAL LYMPHEDEMA TREATMENT MARKET: COMPANY RESEARCH ANALYSIS 51
  • FIGURE 6 GLOBAL LYMPHEDEMA TREATMENT MARKET: INTERVIEW DEMOGRAPHICS 53
  • FIGURE 7 GLOBAL LYMPHEDEMA TREATMENT MARKET: DBMR MARKET POSITION GRID 54
  • FIGURE 8 GLOBAL LYMPHEDEMA TREATMENT MARKET: MARKET END USER COVERAGE GRID 55
  • FIGURE 9 GLOBAL LYMPHEDEMA TREATMENT MARKET: VENDOR SHARE ANALYSIS 56
  • FIGURE 10 GLOBAL LYMPHEDEMA TREATMENT MARKET: SEGMENTATION 61
  • FIGURE 11 INCREASING PREVALENCE OF LYMPHEDEMA AND RISING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE GROWTH OF THE GLOBAL LYMPHEDEMA TREATMENT MARKET IN THE FORECAST PERIOD OF 2023 TO 2030 62
  • FIGURE 12 THE COMPRESSION THERAPY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL LYMPHEDEMA TREATMENT MARKET IN 2023 AND 2030 62
  • FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL LYMPHEDEMA TREATMENT MARKET 72
  • FIGURE 14 GLOBAL LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, 2022 80
  • FIGURE 15 GLOBAL LYMPHEDEMA TREATMENT MARKET: BY TYPE, 2022 90
  • FIGURE 16 GLOBAL LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, 2022 95
  • FIGURE 17 GLOBAL LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, 2022 100
  • FIGURE 18 GLOBAL LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022 104
  • FIGURE 19 GLOBAL LYMPHEDEMA TREATMENT MARKET: BY END USER, 2022 109
  • FIGURE 20 GLOBAL LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022 115
  • FIGURE 21 GLOBAL LYMPHEDEMA TREATMENT MARKET: SNAPSHOT (2022) 121
  • FIGURE 22 GLOBAL LYMPHEDEMA TREATMENT MARKET: COMPANY SHARE 2022 (%) 303
  • FIGURE 23 NORTH AMERICA LYMPHEDEMA TREATMENT MARKET: COMPANY SHARE 2022 (%) 304
  • FIGURE 24 EUROPE LYMPHEDEMA TREATMENT MARKET: COMPANY SHARE 2022 (%) 305
  • FIGURE 25 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: COMPANY SHARE 2022 (%) 306
目次

Global lymphedema treatment market is expected to reach USD 1,866, 576.80thousand by 2030 from USD 902,392.61 thousand in 2022 growing at the CAGR of 9.8% in the forecast period of 2023 to 2030.The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030.

Market Segmentation:

Global Lymphedema Treatment Market, By Treatment Type (Compression Therapy, Surgery, Drug Therapy, Laser Therapy, and Others), Treatment (Primary Lymphedema and Secondary Lymphedema), Affected Area (Genital, Lower Extremity, Upper Extremity, and Others), Age Group (Adult and Geriatric), Route of Administration (Oral, Injectable, and Others), End User (Hospitals, Ambulatory Surgical Centres, Speciality Clinics, and Others), Distribution Channel (Direct tender, Pharmacy stores, and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Hungary, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey, and rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines , Vietnam, and rest of Asia-Pacific, Brazil, Argentina , Peru, and rest of South America, South Africa, Saudi Arabia, U.A.E., Kuwait, Israel, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2030.

Overview of Global Lymphedema Treatment Market Dynamics

  • Driver
  • Rising number of lymphedema cases around the globe
  • Restrain
  • High costs of treatment
  • Opportunity
  • Partnership and agreement by market players

Market Players

Some of the key market players operating in the global lymphedema treatment market are listed below:

  • medi GmbH & Co. KG
  • PAUL HARTMANN AG
  • 3M
  • Convatec Inc.
  • JUZO
  • SIGVARIS GROUP
  • Sanyleg Srl a socio unico
  • AIROS Medical, Inc.
  • Tactile Medical
  • BIOCOMPRESSION SYSTEMS
  • Lohmann & Rauscher GmbH & Co. KG
  • Mego Afek ltd.
  • ThermoTek
  • Cardinal Health
  • Essity (BSN medical GmbH)
  • Smith+Nephew
  • HERANTIS PHARMA Plc
  • Huntleigh Healthcare Limited
  • Avet Pharmaceuticals Inc
  • KOYA MEDICAL

TABLE OF CONTENTS

1 INTRODUCTION 41

  • 1.1 OBJECTIVES OF THE STUDY 41
  • 1.2 MARKET DEFINITION 41
  • 1.3 OVERVIEW OF THE GLOBAL LYMPHEDEMA TREATMENT MARKET 41
  • 1.4 LIMITATIONS 43
  • 1.5 MARKETS COVERED 43

2 MARKET SEGMENTATION 46

  • 2.1 MARKETS COVERED 46
  • 2.2 GEOGRAPHICAL SCOPE 47
  • 2.3 YEARS CONSIDERED FOR THE STUDY 48
  • 2.4 CURRENCY AND PRICING 48
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 49
  • 2.6 MULTIVARIATE MODELLING 52
  • 2.7 PRODUCT TYPE LIFELINE CURVE 52
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 53
  • 2.9 DBMR MARKET POSITION GRID 54
  • 2.10 MARKET END USER COVERAGE GRID 55
  • 2.11 VENDOR SHARE ANALYSIS 56
  • 2.12 SECONDARY SOURCES 57
  • 2.13 ASSUMPTIONS 57

3 EXECUTIVE SUMMARY 58

4 PREMIUM INSIGHTS 62

  • 4.1 PESTEL'S ANALYSIS 63
  • 4.2 PORTER'S MODEL 64

5 PIPELINE ANALYSIS FOR GLOBAL LYMPHEDEMA TREATMENT MARKET 65

6 EPIDEMIOLOGY 66

7 REGULATORY GUIDELINES FOR GLOBAL LYMPHEDEMA TREATMENT MARKET 67

  • 7.1 U.S. 67
  • 7.2 EUROPE 68
  • 7.3 INDIA 68
  • 7.4 MEXICO 69
  • 7.5 CANADA 69

8 MARKET OVERVIEW 71

  • 8.1 DRIVERS 73
    • 8.1.1 RISE IN THE NUMBER OF LYMPHEDEMA CASES GLOBALLY 73
    • 8.1.2 INCREASE IN THE PREVALENCE OF CANCERS 73
    • 8.1.3 INCREASING NUMBER OF HEALTHCARE FACILITIES 74
    • 8.1.4 AVAILABILITY OF MULTIPLE THERAPIES FOR LYMPHEDEMA 74
  • 8.2 RESTRAINTS 75
    • 8.2.1 HIGH COST OF TREATMENT 75
    • 8.2.2 LACK OF AWARENESS ABOUT THE DISEASE 76
  • 8.3 OPPORTUNITIES 76
    • 8.3.1 INCREASING DRUG APPROVALS 76
    • 8.3.2 RISING PARTNERSHIPS AND AGREEMENTS BY MAJOR PLAYERS 77
  • 8.4 CHALLENGES 77
    • 8.4.1 NO PERMANENT CURE FOR LYMPHEDEMA 77
    • 8.4.2 LIMITED REIMBURSEMENT SCENARIO 77

9 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE 79

  • 9.1 OVERVIEW 80
  • 9.2 COMPRESSION THERAPY 81
    • 9.2.1 COMPRESSION PUMPS 82
    • 9.2.2 COMPRESSION GARMENTS 82
      • 9.2.2.1 COMPRESSION STOCKINGS 82
      • 9.2.2.2 COMPRESSION SLEEVES 82
      • 9.2.2.3 OTHERS 83
    • 9.2.3 COMPRESSION BANDAGES & WRAPS 83
    • 9.2.4 OTHERS 83
      • 9.2.4.1 STATIC COMPRESSION THERAPY 83
      • 9.2.4.2 DYNAMIC COMPRESSION THERAPY 83
  • 9.3 SURGERY 84
    • 9.3.1 LYMPHOVENOUS TRANSPLANT 84
    • 9.3.2 LYMPHATICOVENOUS ANASTOMOSIS 84
    • 9.3.3 LIPOSUCTION 85
    • 9.3.4 OTHERS 85
  • 9.4 DRUG THERAPY 85
    • 9.4.1 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) 86
    • 9.4.2 RETINOIDS 86
    • 9.4.3 ANTIBIOTICS 86
    • 9.4.4 OTHERS 86
  • 9.5 LASER THERAPY 87
  • 9.6 OTHERS 88

10 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY TYPE 89

  • 10.1 OVERVIEW 90
  • 10.2 SECONDARY LYMPHEDEMA 91
  • 10.3 PRIMARY LYMPHEDEMA 92
    • 10.3.1 LYMPHEDEMA PRAECOX (MEIGE DISEASE) 92
    • 10.3.2 CONGENITAL LYMPHEDEMA 93
    • 10.3.3 LYMPHEDEMA TARDA 93

11 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA 94

  • 11.1 OVERVIEW 95
  • 11.2 LOWER EXTREMITY 96
  • 11.3 UPPER EXTREMITY 97
  • 11.4 GENITALIA 98

12 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP 99

  • 12.1 OVERVIEW 100
  • 12.2 ADULT 101
  • 12.3 GERIATRIC 102
  • 12.4 PEDIATRIC 102

13 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 103

  • 13.1 OVERVIEW 104
  • 13.2 ORAL 105
  • 13.3 INJECTABLE 106
  • 13.4 TOPICAL 107

14 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY END USER 108

  • 14.1 OVERVIEW 109
  • 14.2 HOSPITAL 110
  • 14.3 SPECIALTY CLINICS 111
  • 14.4 AMBULATORY SURGICAL CENTERS 112
  • 14.5 OTHERS 113

15 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL 114

  • 15.1 OVERVIEW 115
  • 15.2 PHARMACY STORES 116
  • 15.3 DIRECT TENDER 117
  • 15.4 OTHERS 118 

16 GLOBAL LYMPHEDEMA TREATMENT MARKET, BY REGION 119

  • 16.1 OVERVIEW 120
  • 16.2 NORTH AMERICA 124
    • 16.2.1 U.S. 128
    • 16.2.2 CANADA 131
    • 16.2.3 MEXICO 135
  • 16.3 EUROPE 138
    • 16.3.1 GERMANY 142
    • 16.3.2 FRANCE 146
    • 16.3.3 U.K. 150
    • 16.3.4 ITALY 154
    • 16.3.5 RUSSIA 157
    • 16.3.6 SPAIN 161
    • 16.3.7 TURKEY 165
    • 16.3.8 NETHERLANDS 169
    • 16.3.9 SWITZERLAND 173
    • 16.3.10 BELGIUM 177
    • 16.3.11 POLAND 181
    • 16.3.12 AUSTRIA 185
    • 16.3.13 HUNGARY 189
    • 16.3.14 NORWAY 193
    • 16.3.15 IRELAND 197
    • 16.3.16 LITHUANIA 201
    • 16.3.17 REST OF EUROPE 205
  • 16.4 ASIA-PACIFIC 206
    • 16.4.1 CHINA 210
    • 16.4.2 JAPAN 214
    • 16.4.3 INDIA 218
    • 16.4.4 SOUTH KOREA 221
    • 16.4.5 AUSTRALIA 225
    • 16.4.6 INDONESIA 229
    • 16.4.7 SINGAPORE 233
    • 16.4.8 PHILIPPINES 237
    • 16.4.9 THAILAND 241
    • 16.4.10 MALAYSIA 245
    • 16.4.11 VIETNAM 249
    • 16.4.12 REST OF ASIA-PACIFIC 253 
  • 16.5 SOUTH AMERICA 254
    • 16.5.1 BRAZIL 259
    • 16.5.2 ARGENTINA 264
    • 16.5.3 PERU 269
    • 16.5.4 REST OF SOUTH AMERICA 274
  • 16.6 MIDDLE EAST AND AFRICA 275
    • 16.6.1 SOUTH AFRICA 279
    • 16.6.2 SAUDI ARABIA 283
    • 16.6.3 EGYPT 287
    • 16.6.4 U.A.E. 291
    • 16.6.5 ISRAEL 294
    • 16.6.6 KUWAIT 298
    • 16.6.7 REST OF MIDDLE EAST AND AFRICA 302

17 GLOBAL LYMPHEDEMA TREATMENT MARKET, COMPANY LANDSCAPE 303

  • 17.1 COMPANY SHARE ANALYSIS: GLOBAL 303
  • 17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 304
  • 17.3 COMPANY SHARE ANALYSIS: EUROPE 305
  • 17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 306

18 COMPANY PROFILE 307

  • 18.1 TACTILE MEDICAL 307
    • 18.1.1 COMPANY SNAPSHOT 307
    • 18.1.2 REVENUE ANALYSIS 307
    • 18.1.3 COMPANY SHARE ANALYSIS 308
    • 18.1.4 PRODUCT PORTFOLIO 308
    • 18.1.5 RECENT DEVELOPMENT 308
  • 18.2 ESSITY (BSN MEDICAL GMBH) 309
    • 18.2.1 COMPANY SNAPSHOT 309
    • 18.2.2 COMPANY SHARE ANALYSIS 309
    • 18.2.3 PRODUCT PORTFOLIO 310
    • 18.2.4 RECENT DEVELOPMENT 310
  • 18.3 3M 311
    • 18.3.1 COMPANY SNAPSHOT 311
    • 18.3.2 REVENUE ANALYSIS 311
    • 18.3.3 COMPANY SHARE ANALYSIS 312
    • 18.3.4 PRODUCT PORTFOLIO 312
    • 18.3.5 RECENT DEVELOPMENTS 312